Efek Terapi Citicoline terhadap Pemulihan Kognitif dan Motorik Pasien Stroke Iskemik Akut dengan Polimorfisme ApoE4 rs429358 dan rs7412


  • Faizal Muhammad Universitas Sebelas Maret
  • Afifah Syifaul Ummah Universitas Sebelas Maret
  • Farida Aisyah Universitas Sebelas Maret
  • Rivan Danuaji Universitas Sebelas Maret
  • Subandi Universitas Sebelas Maret
  • Diah Kurnia Mirawati Universitas Sebelas Maret




Citicoline, cognitive, motoric, ischemic stroke, polymorphism


Citicoline has a neuroprotectant effect, especially in mild-to-moderate stroke. The presence of the ε4 allele in the ApoE gene is associated with a severe acute ischemic stroke (AIS) phenotype, in addition to neurodegenerative risk This study aims to determine the effect of citicoline on cognitive and motoric recovery in severe AIS biomolecularly, such as ApoE4 rs429358 and rs7412 polymorphisms. A 64-year-old woman was diagnosed with AIS with a 6-hour onset and with a NIHSS score of 25 and MMSE score of 21. The patient’s AIS was biomolecularly severe as proven by PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) ApoE4 which yielded 482 bp at rs429358 (codon 112) and 249 bp 167 bp at rs7412 (codon 158) on electrophoretic visualization. The patient received 3x 500 mg intravenous citicoline for 4 days followed by another 1000 mg of citicoline intravenous during polyclinic control for 5 consecutive days. On the 9th day, the patient experienced improvement in cognitive function with an MMSE score of 29 and superior (4/5) and inferior (5/5) motoric strength. Citicoline is a neuroprotectant agent that is beneficial for the recovery of cognitive and motoric function in biomolecularly severe SIA (ApoE4, C/C, Arg112/Arg158) because it can save the penumbra area from infarction.


Download data is not yet available.


Murphy SJ, Werring DJ. Stroke: Causes and clinical features. Medicine (Baltimore) 2020;48(9):561–6.

Béjot Y, Daubail B, Giroud M. Epidemiology of stroke and transient ischemic attacks: Current knowledge and perspectives. Rev Neurol (Paris) 2016;172(1):59–68.

Danuaji R, Suroto S, Purwanto B, Indarto D, Muhammad F, Mirawati DK, et al. Association between carotid intima media thickness and acute ischemic stroke at an Indonesian tertiary referral hospital. J Taibah Univ Med Sci. 2023;18(4):771–7.

Venketasubramanian N, Yudiarto FL, Tugasworo D. Stroke burden and stroke services in Indonesia. Cerebrovasc Dis Extra 2022;12(1):53–7.

Qiu S, Xu Y. Guidelines for acute ischemic stroke treatment. Neurosci Bull. 2020;36(10):1229–32.

Grieb P. Neuroprotective properties of citicoline: Facts, doubts and unresolved issues. CNS Drugs 2014;28(3):185–93.

Secades JJ, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Martínez-Vila E, Ríos J, et al. Citicoline for acute ischemic stroke: A systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. J Stroke Cerebrovasc Dis. 2016;25(8):1984–96.

Qiao SY, Shang K, Chu YH, Yu HH, Chen X, Qin C, et al. Apolipoprotein E ε4 polymorphism as a risk factor for ischemic stroke: A systematic review and meta-analysis. Dis Markers 2022;2022:1–30.

Zhong L, Xie YZ, Cao TT, Wang Z, Wang T, Li X, et al. A rapid and cost-effective method for genotyping apolipoprotein E gene polymorphism. Mol Neurodegener. 2016;11(1):2.

Rajan KB, Aggarwal NT, Schneider JA, Wilson RS, Everson-Rose SA, Evans DA. Role of APOE ε4 allele and incident stroke on cognitive decline and mortality. Alzheimer Dis Assoc Disord. 2016;30(4):318–23.

Agarwal A, Vishnu VY, Sharma J, Bhatia R, Garg A, Dwivedi S, et al. Citicoline in acute ischemic stroke: A randomized controlled trial. In: De Rosa S, editor. PLoS One 2022;17(5):e0269224.

Kloske CM, Gearon MD, Weekman EM, Rogers C, Patel E, Bachstetter A, et al. Association between APOE genotype and microglial cell morphology. J Neuropathol Exp Neurol. 2023;82(7):620–30.

Zhao L, Su G, Chen L, Yan Q, Wang X, Yuan W, et al. Apolipoprotein E polymorphisms are associated with ischemic stroke susceptibility in a Northwest China Han population. Biosci Rep. 2017;37(6):BSR20171088. doi: 10.1042/BSR20171088.

Li Y, Chang J, Chen X, Liu J, Zhao L. Advances in the study of APOE and innate immunity in Alzheimer’s disease. J Alzheimer’s Dis. 2023;93(4):1195–210.

Martinov M, Gusev E. Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke. J Exp Pharmacol. 2015;7:17-28. doi: 10.2147/JEP.S63544. eCollection 2015.

Martí-Carvajal AJ, Valli C, Martí-Amarista CE, Solà I, Martí-Fàbregas J, Bonfill Cosp X. Citicoline for treating people with acute ischemic stroke. Cochrane Database Syst Rev. 2020;8(8):CD013066. doi: 10.1002/14651858.CD013066.pub2.

Gareri P, Castagna A, Cotroneo AM, Putignano S, De Sarro G, Bruni AC. The role of citicoline in cognitive impairment: Pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. Clin Interv Aging 2015;10:1421.



How to Cite

Muhammad, F., Ummah, A. S., Aisyah, F., Danuaji, R., Subandi, & Mirawati, D. K. (2023). Efek Terapi Citicoline terhadap Pemulihan Kognitif dan Motorik Pasien Stroke Iskemik Akut dengan Polimorfisme ApoE4 rs429358 dan rs7412. Cermin Dunia Kedokteran, 50(11), 611–626. https://doi.org/10.55175/cdk.v50i11.1016